| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Nuclear Medicine Department, Ospedale Maggiore-IRCCS, Milan
Nuclear Medicine Division, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan
Medical Oncology Division, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
Correspondence: For correspondence or reprints contact: Massimo Gasparini, MD, Nuclear Medicine Department,Padiglione Granelli, Ospedale Maggiore, IRCCS, Via Francesco Sforza, 35, 20122 Milano, Italy.
ABSTRACT
Patients with diffuse large cell lymphoma may achieve complete remission (CR) after chemotherapy, and the time to reach CR may be predictive of treatment outcome. Partial remission, or recurrence from CR, is associated with poor survival. Gallium-67 imaging has proven to be useful in evaluating lymphoma patients. In tumor models, this radiotracer is an indicator of tumor viability.Gallium-67 uptake is seen only in avid and viable lymphoma tissue, not in fibrotic or necrotic tissue. Inthis study,we prospectively assessed the ability of this radiotracer to define residual disease. In addition, we evaluated the possibility of predicting the clinical outcome in patients with diffuse cell lymphoma on the basis of scan positivity during chemotherapy. Methods: Thirty-three consecufive patients with histologically proven diffuse large cell lymphoma were investigated with 67Ga scintigraphy 48–72hr after injection of 185–259 MBq 67Ga-citrate for staging and during follow-upafter four to six cycles of intensive chemotherapy. Patients were monitored for a mean of 56.0 mo (range 7–90 mo), and they were restaged using physical examination, CT and all necessary imaging modalities. Results: Patients were divided into two groups according to the positivity or negativity of 67Ga scan after four to six cycles of chemotherapy. Of the 33 patients studied, 14 (42.4%) showed persistent abnormal uptake of 67Ga-citrate after four to six cycles of chemotherapy. In this group, 9 patients (64.2%) died of lymphoma at a meanof 24.3 mo from presentation with the diagnosis (range 7–71 mo). Four patients had no evidence of disease at an average of 71.7 mo after diagnosis, and 1 patient was considered to be in partial remission. In the second group of 19 67Ga-negative patients, after four to six cycles of chemotherapy, 4 died and 15 are alive and considered to be in CR. A statistical analysis of the association between 67Ga scan results after four to six cycles of chemotherapy and survival was performed using the log-rank test; there was a statistically significant association between scan results and survival (p = 0.00125). Conclusion: We conclude that 67Ga scintigraphy is an excellent predictor of residual tumor viability in lymphoma patients and that persistent positivity of the scan predicts poor outcome and may justify a change in treatment.
Key Words: gallium scintigraphy • non-Hodgkin's lymphoma • chemotherapy
This article has been cited by other articles:
|
|
 |
|
  R. Bar-Shalom, N. Yefremov, N. Haim, E. J. Dann, R. Epelbaum, Z. Keidar, D. Gaitini, A. Frenkel, and O. Israel Camera-based FDG PET and 67Ga SPECT in Evaluation of Lymphoma: Comparative Study Radiology, May 1, 2003; 227(2): 353 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. J. Lowe and G. A. Wiseman Assessment of Lymphoma Therapy Using 18F-FDG PET J. Nucl. Med., August 1, 2002; 43(8): 1028 - 1030. [Full Text] [PDF]
|
|
|
|
 |
|
 E. F. Patz Jr., J. Connolly, and J. Herndon Prognostic Value of Thoracic FDG PET Imaging After Treatment for Non-Small Cell Lung Cancer Am. J. Roentgenol., March 1, 2000; 174(3): 769 - 774. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
